Holen Sie sich die Stockscreener-App
1.52
0.65%
-0.01
Handel nachbörslich:
1.62
0.10
+6.58%
Senti Biosciences Inc Aktie (SNTI) Neueste Nachrichten
Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - The Manila Times
Senti Biosciences to present at Webull Financial Corporate Connect webinar. - AInvest
Senti Bio CEO to Showcase Gene Circuit Platform at Webull's Biotech Investment Series - Stock Titan
Senti Biosciences Posts Increased Losses Amid Strategic Moves and Raising $35.2M in Private Placement - AInvest
Laidlaw Initiates Coverage on Senti Bio with Buy Rating and $5 Target Price - AInvest
Is This a Bottoming Phase for Senti Biosciences Inc.2025 Valuation Update & Risk Managed Investment Signals - beatles.ru
Senti Biosciences Reports Increased Losses Amid Strategic Moves - TipRanks
Senti Biosciences shares rise 3.38% after-hours after announcing Phase 2 dose selection for SENTI-202. - AInvest
Senti Biosciences shares fall 1.32% intraday after announcing participation in a Virtual Investor 'What This Means' segment. - AInvest
Senti Bio Participates in Virtual Investor 'What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia - The Manila Times
Breakthrough AML Treatment Advances: Senti Bio Reveals Phase 2 Dosing Strategy for Novel CAR-NK Cell Therapy - Stock Titan
Momentum divergence signals in Senti Biosciences Inc. chartTrading Opportunities Forecast by AI Insight - Newser
What makes Senti Biosciences Inc. stock price move sharplyReal Market Tracker with Price Action Tools - Newser
Senti Biosciences Inc. stock chart pattern explainedLow Exposure Strategy with Sector Analysis - Newser
Senti Biosciences Inc. Stock Fails to Break Resistance Traders ReactIntraday Trend Analysis for Fast Gains Released - beatles.ru
Using data tools to time your Senti Biosciences Inc. exitBreakout Monitoring with Momentum Analysis - Newser
Chardan Capital Reaffirms “Buy” Rating for Senti Biosciences (NASDAQ:SNTI) - Defense World
Senti Biosciences Inc Reports Q2 2025 Earnings: EPS at -$0.56, Revenue Misses Estimates at $0 Million - AInvest
Senti Biosciences: Chardan Capital Raises Buy Rating, PT to $12 - AInvest
Will Senti Biosciences Inc. announce a stock splitFree Technical Signal Summary - thegnnews.com
Senti Biosciences: A High-Risk Bet on Biotech's Future? - AInvest
Senti Biosciences completes dose finding in AML therapy trial By Investing.com - Investing.com Australia
Senti Biosciences completes dose finding in AML therapy trial - Investing.com
Senti Bio reports Q2 results, SENTI-202 clinical development advances. - AInvest
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 - The Manila Times
Senti Bio Advances AML Treatment: Phase 2 Dose Confirmed, FDA Orphan Drug Status Secured - Stock Titan
How Senti Biosciences Inc. stock performs during market volatilityTen-Year Sector Performance and Summary Analysis - Newser
Sandstorm Gold Royalties Backs Royal Gold’s Kansanshi Acquisition - The Globe and Mail
Senti Biosciences shares rise 3.49% premarket after confirming recommended Phase 2 dose for SENTI-202. - AInvest
Tools to assess Senti Biosciences Inc.’s risk profileAnnual Market Behavior and Sector Summary - Newser
Will Senti Biosciences Inc. stock recover after recent dropIn-Depth Stock Trading Volume Analysis - Newser
Is Senti Biosciences Inc. stock overhyped or has real potentialConsistent Gain Plan with AI Support - Newser
Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia - The Manila Times
Breakthrough AML Treatment: Senti Bio's Cell Therapy Shows 67% Complete Remission at Phase 2 Dose - Stock Titan
Senti Biosciences Inc. Forms Double Bottom Pattern — Eyes on BreakoutConsistent Gain Investment Strategies Emerge - metal.it
Is Senti Biosciences Inc. stock entering bullish territoryFree Sector Based Breakout Stock Forecast - Newser
What is Senti Biosciences Inc. company’s growth strategyAchieve consistent profits with proven methods - Jammu Links News
How does Senti Biosciences Inc. generate profit in a changing economyCapitalize on market momentum for maximum gains - Jammu Links News
What are the technical indicators suggesting about Senti Biosciences Inc.Capitalize on market momentum for maximum gains - Jammu Links News
Is Senti Biosciences Inc. stock overvalued or undervaluedFree Stock Market Real-Time Monitoring - Jammu Links News
Why Senti Biosciences Inc. stock attracts strong analyst attentionFast Entry Strategy with Price Prediction - Newser
What catalysts could drive Senti Biosciences Inc. stock higher in 2025High-profit capital plays - Jammu Links News
Is Senti Biosciences Inc. a good long term investmentConsistently outstanding ROI - Jammu Links News
How does Senti Biosciences Inc. compare to its industry peersIdentify undervalued stocks poised to rally - Jammu Links News
What institutional investors are buying Senti Biosciences Inc. stockAchieve breakthrough investment performance - Jammu Links News
How many analysts rate Senti Biosciences Inc. as a “Buy”AI Powered Ideas With High Returns - Jammu Links News
Long term hold vs stop loss in Senti Biosciences Inc.Daily Technical Forecast for Quick Gains - Newser
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):